Product Name | Encapsulated Drugs | Type of Liposomes | Indications | Lipid Composition | Particle Size | Status | Reference |
---|---|---|---|---|---|---|---|
nm | |||||||
CPX-1 | Irinotecan and floxuridine (1:1) | ULVs | Advanced solid tumors, including colorectal cancer | DSPC, DSPG, and cholesterol | 100 | Phase II | NCT00361842a (accessed on Apr 14, 2015); Batist et al. (2009) |
EndoTAG-1 | Paclitaxel | Cationic liposomes | Solid tumors | DOTAP, DOPC | 180–200 | Phase II | Fasol et al. (2012); Lohr et al. (2012); Awada et al. (2014) |
LEP-ETU | Paclitaxel | Anionic liposomes | Metastatic breast cancer | DMPC, DOPC, DSPC, cholesterol, and cardiolipin | 100–160 | Phase II | NCT01190982a (accessed on Apr 15, 2015); Zhang et al. (2005); Slingerland et al. (2013) |
MBP-426 | Oxaliplatin | Tf-conjugated liposomes | Gastric, gastroesophageal, esophageal adenocarcinomas | DSPC, DSPE-PEG2000Da, cholesterol and Tf -conjugated NGPE | 180 | Phase II | Suzuki et al. (2008); van der Meel et al. (2013) |
OSI-211 | Lurtotecan | SUVs | NSCLC, breast, colorectal, ovarian, head and neck cancers | Soy PC and cholesterol | 100 | Phase II | Gamucci et al. (2000); Duffaud et al. (2004); Seiden et al. (2004) |
↵a ClinicalTrials.gov identifier
DSPG, 1,2-distearoyl-sn-glycerol-3-phospho-(1′-rac-glycerol); NGPE, N-glutaryl phosphatidylethanolamine; NSCLC, non-small cell lung cancer; Tf, transferrin